Hitzeschockproteine, Immunkompetenz und Vakzinierung[1]

Hitzeschockproteine (HSP) sind hochkonservierte, zytoprotektive Proteine, die unter Zellstress überexprimiert werden. Die Erforschung ihrer immunologischen Eigenschaften hat sich in den letzten Jahren zu einer neuen und vielversprechenden Disziplin der Immunologie etabliert. Zahlreiche präklinische Arbeiten zeigen, dass HSP, wenn sie sich im extrazellulären Milieu befinden, das angeborene und das adaptive Immunsystem effizient stimulieren können. Derzeit laufen HSP-basierte Vakzinierungsansätze in klinischen Studien der Phase II und III, um das „Proof of principle” und die anti-tumorale Immunantwort in vivo nachzuweisen.

Die Hyperthermie-Behandlung von Tumoren hat neben dem direkten zytotoxischen Effekt auch eine indirekte immunmodulatorische Wirkung, indem die Expression von HSP induziert wird und durch die Hyperthermie-bedingte Nekrose auch HSP freigesetzt werden.

Ziel der aktuellen Forschung ist, neue Erkenntnisse über die durch Hyperthermie-Behandlung induzierte Immunantwort zu erhalten, sowie Änderungen in der Tumorphysiologie besser zu verstehen, um die Effektivität der Hyperthermiebehandlung und der HSP-basierten Vakzinierungen für Patienten mit fortgeschrittenen Tumoren zu verbessern.

1 Dieses Forschungsprojekt wird durch das SFB455-Projekt B9 und das Krebshilfe-Projekt 7023011-Is/2 gefördert.

Literatur

• 1 Akira S. Mammalian Toll-like receptors.  Curr Opin Immunol. 2003;  15 5-11
• 2 Atanackovic D, Nierhaus A, Neumeier M, Hossfeld D K, Hegewisch-Becker S. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.  Cancer Immunol Immunother. 2002;  51 603-613
• 3 Asea A, Kraeft S K, Kurt-Jones E A. et al . HSP70 stimulates cytokine production through a CD14 dependent pathway, demonstrating a dual role as a chaperone and cytokine.  Nat Med. 2000;  6 435-442
• 4 Asea A, Rehli M, Kabingu E. et al . Novel signal transduction pathway utilized by extracellular HSP70: role of TLR2 and TLR4.  J Biol Chem. 2002;  277 15028-15034
• 5 Banchereau J, Steinmann R M. Dendritic cells and the control of immunity.  Nature. 1999;  392 245-252
• 6 Basu S, Binder R J, Ramalingam T, Srivastava P K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.  Immunity. 2001;  14 303-313
• 7 Bausinger H, Lipsker D, Ziylan U. et al . Endotoxin-free heat-shock protein 70 fails to induce APC activation.  Eur J Immunol. 2002;  32 3708-3713
• 8 Becker T, Hartl F U, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes.  J Cell Biol. 2002;  158 1277-1285
• 9 Belli F, Testori A, Rivoltini L. et al . Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.  J Clin Oncol. 2002;  20 4169-4180
• 10 Bethke K, Staib F, Distler M. et al . Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60.  J Immunol. 2002;  169 6141-6148
• 11 Binder R J, Blachere N E, Srivastava P K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules.  J Biol Chem. 2001;  276 17 163-17 171
• 12 Breloer M, More S, Dorner B, Fleischer B, von Bonin A. Hitzeschockproteine als Gefahrensignale: HSP60 verstärkt die antigenspezifische Aktivierung primärer T-Zellen.  Immunologie Aktuell. 2001;  2 64-66
• 13 Buchner J, Walter S. Molecular chaperones-Cellular machines for protein folding.  Angew Chem Int Ed. 2002;  41 1098-1113
• 14 Bukau B, Horwich A L. The HSP70 and HSP60 chaperone machines.  Cell. 1998;  92 351-366
• 15 Castelli C, Ciupitu A M, Rini F. et al . Human heat shock 70 peptide complexes specifically activate antimelanoma T cells.  Cancer Res. 2001;  61 222-227
• 16 Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60 kDa heat shock protein. A danger signal to the innate immune response.  J Immunol. 1999;  162 3212-3219
• 17 Ciupitu A M, Petersson M, Odonnell C L. et al . Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes.  J Exp Med. 1998;  187 685-691
• 18 Delneste Y, Magistrelli G, Gauchat J F. et al . Involvement of LOX-1 in Dendritic Cell-Mediated Antigen Cross-Presentation.  Immunitiy. 2002;  17 352-362
• 19 Falk M, Issels R D. Hyperthermia in oncology.  Int J Hyperthermia. 2001;  17 1-18
• 20 Flohe S B, Bruggemann J, Lendemans S. et al . Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype.  J Immunol. 2003;  170 2340-2348
• 21 Fuller J, Issels R, Slosman D, Guillet J G, Soussi T, Polla B S. Cancer and the heat shock response.  Eur J Cancer. 1994;  12 1884-1891
• 22 Gehrmann M, Pfister K, Hutzler P, Gastpar R, Margulis B, Multhoff G. Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels.  Biol Chem. 2002;  383 1715-1725
• 23 Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis J J, Srivastava P K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparation: a pilot study.  Int J Cancer. 2000;  88 232-238
• 24 Janeway  C A Jr., Medzhitov R. Innate immune recognition.  Annu Rev Immunol. 2002;  20 197-216
• 25 Keilholz U, Weber J, Finke J H. et al . Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.  J Immunother. 2002;  25 97-138
• 26 Kuppner M, Gastpar R, Gelwer S. et al . The role of heat shock protein (HSP70) in dendritic cell maturation: HSP70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocytes precursors.  Eur J Immunol. 2001;  31 1602-1609
• 27 Matzinger P. Tolerance, danger, and the extended family.  Annu Rev Immunol. 1994;  12 991-945
• 28 Medzhitov R, Preston-Hurlburt P, Janeway C A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.  Nature. 1997;  388 394-397
• 29 Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile R G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock proteins expression.  Nat Med. 1998;  4 581-587
• 30 Milani V, Noessner E, Ghose S. et al . Heat shock protein 70: role in antigen presentation and immune stimulation.  Int J Hyperthermia. 2002;  18 563-575
• 31 Milarski K L, Morimoto R I. Expression of human HSP70 during the synthetic phase of the cell cycle.  Proc Natl Acad Sci USA. 1986;  83 9517-9521 SE>
• 32 Multhoff G. Activation of natural killer cells by heat shock protein 70.  Int J Hyperthermia. 2002;  18 576-585
• 33 Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumour cells: a recognition structure for natural killer cells.  J Immunol. 1997;  158 4341-4350
• 34 Noessner E, Gastpar R, Milani V. et al . Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells.  J Immunol. 2002;  169 5424-5432
• 35 Parmiani G, Castelli C, Dalerba P. et al . Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?.  J Natl Cancer Inst. 2002;  94 805-818
• 36 Singh-Jasuja H, Hilf N, Arnold-Schild D, Schild H. The role of heat shock proteins and their receptors in the activation of the immune system.  Biol Chem. 2001;  382 629-636
• 37 Singh-Jasuja H, Toes R E, Spee P. et al . Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.  J Exp Med. 2000;  191 1965-1974
• 38 Singh-Jasuja H, Scherer H U, Hilf N, Arnold-Schild D, Rammensee H G, Toes R EM, Schild A. The heat shock protein gp96 induces maturation of dendritic cells and down regulation of its receptor.  Eur J Immunol. 2000;  30 2211-2215
• 39 Somersan S, Larsson M, Fonteneau J, Basu S, Srivastava P, Bhardway N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.  J Immunol. 2001;  167 4844-4852
• 40 Srivastava P K. Immunotherapy of human cancer: lessons from mice.  Nature Immunology. 2000;  1 363-366
• 41 Srivastava P K, DeLeo A B, Old L J. Tumor rejection antigens of chemically induced sarcomas in inbred mice.  Proc Natl Acad Sci USA. 1986;  83 3407-3411
• 42 Srivastava P, Menoret A, Basu S, Binder R, McQuade K. Heat shock protein come of age: primitive functions acquire new roles in an adaptive world.  Immunity. 1998;  8 657-665
• 43 Srivastava P K, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy.  Curr Opin Immunol. 1994;  6 728-732
• 44 Stewart J R, Gibbs F A. Hyperthermia in the treatment of cancer. Perspectives on its promise and its problems.  Cancer. 1984;  54 2823-2830
• 45 Udono H, Srivastava P K. Heat shock protein 70-associated peptides elicit specific cancer immunity.  J Exp Med. 1993;  178 1391-96
• 46 Udono H, Srivastava P K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, HSP90 and HSP70.  J Immunol. 1994;  152 5398-5403
• 47 Vabulas R M, Ahmad-Nejad P, da Costa C. et al . Endocytosed HSP60 s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells.  J Biol Chem. 2001;  276 31 332-31 339
• 48 Vabulas R M, Ahmad-Nejad P, Ghose S, Kirschning C J, Issels R D, Wagner H. HSP70 as endogenous stimulus of Toll/interleukin-1 receptor signal pathway.  J Biol Chem. 2002;  277 15 107-15 112
• 49 Vabulas R M, Braedel S, Hilf N. et al . The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway.  J Biol Chem. 2002;  277 20 847-20 853
• 50 Vabulas R M, Wagner H, Schild H. Heat shock proteins as Ligands for Toll-like receptors.  Curr Top Microbiol Immunol. 2002;  270 169-184
• 51 Wang X Y, Kazim L, Repasky E, Subjeck J. Characterization of heat shock protein 110 and glucose-regulated 170 as cancer vaccine and the effect of fever-range hyperthermia on vaccine activity.  J Immunol. 2001;  165 490-497
• 52 Wells A D, Malkovsky M. Heat shock proteins, tumour immunogenicity and antigen presentation: an integrated view.  Immunol Today. 2000;  21 129-132

1 Dieses Forschungsprojekt wird durch das SFB455-Projekt B9 und das Krebshilfe-Projekt 7023011-Is/2 gefördert.